Indication
Pancreatic Tumors
1 clinical trial
1 product
Product
Lanreotide AutogelClinical trial
Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 DaysStatus: Completed, Estimated PCD: 2019-10-16